Zobrazeno 1 - 10
of 228
pro vyhledávání: '"Alan Sandler"'
Autor:
Namrata S Patil, Wei Zou, Simonetta Mocci, Alan Sandler, Marcus Ballinger, Susan Flynn, Marcin Kowanetz, Priti S Hegde
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0246486 (2021)
PurposeOverall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum C-reactive protein (CRP) in non-small cell lung cancer (NSCLC) trials with atezolizumab (
Externí odkaz:
https://doaj.org/article/3cd9ebe18a8747349ef4cac75da859ee
Autor:
Christina A. Clarke, Manali Patel, Heather A. Wakelee, Iona Cheng, Alan Sandler, Margaret McCusker, Shih-Wen Lin, Juan Yang, Scarlett Lin Gomez
Background: Lung cancer is the leading cause of cancer-related death among Chinese Americans. A detailed examination of incidence trends by immigration status and histology may inform the etiology of lung cancer in this growing population.Methods: Ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e0c2009e21c5327617ceebe5d884b91
https://doi.org/10.1158/1055-9965.c.6516495
https://doi.org/10.1158/1055-9965.c.6516495
Supplemental Data from Incidence Trends of Lung Cancer by Immigration Status among Chinese Americans
Autor:
Christina A. Clarke, Manali Patel, Heather A. Wakelee, Iona Cheng, Alan Sandler, Margaret McCusker, Shih-Wen Lin, Juan Yang, Scarlett Lin Gomez
Supplemental Data: Cancer case counts population estimates and incidence rates by histology and year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a42ca4d42dd247734a56f13669d435f4
https://doi.org/10.1158/1055-9965.22438725
https://doi.org/10.1158/1055-9965.22438725
Autor:
René Bruno, Jean-Charles Soria, David Gandara, Achim Rittmeyer, Amita Joshi, Alan Sandler, Marcus Ballinger, Pei He, Mark Stroh, Sandhya Girish, Helen Winter, Charles Ferté, Jin Y. Jin, Laurent Claret
Supplementary Figure S1-S6; Supplementary Table S1-S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98d20a06298c005f1741128bfcbf841c
https://doi.org/10.1158/1078-0432.22470293.v1
https://doi.org/10.1158/1078-0432.22470293.v1
Autor:
Geoffrey I. Shapiro, Wei Guo, Florentina Teofilovici, Kwok-Kin Wong, Suresh Ramalingam, Mark Huberman, Harry Harper, Timothy Webb, Chandra P. Belani, Alan Sandler, Lin-Chi Chen, Julie Brahmer, Philip Bonomi, Lecia V. Sequist, Howard West, Ravi Salgia, Eugene Paschold, Leora Horn, Vojo Vukovic, Marianna Koczywas, Iman El-Hariry, Jonathan Goldman, Mark A. Socinski
PDF file - 91K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34459da61b5b15889b0d3dcf34581138
https://doi.org/10.1158/1078-0432.22452692.v1
https://doi.org/10.1158/1078-0432.22452692.v1
Autor:
René Bruno, Jean-Charles Soria, David Gandara, Achim Rittmeyer, Amita Joshi, Alan Sandler, Marcus Ballinger, Pei He, Mark Stroh, Sandhya Girish, Helen Winter, Charles Ferté, Jin Y. Jin, Laurent Claret
Purpose: Standard endpoints often poorly predict overall survival (OS) with immunotherapies. We investigated the predictive performance of model-based tumor growth inhibition (TGI) metrics using data from atezolizumab clinical trials in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81c9e81e799ad88b584d3b0e6967e6d6
https://doi.org/10.1158/1078-0432.c.6527507.v1
https://doi.org/10.1158/1078-0432.c.6527507.v1
Autor:
Geoffrey I. Shapiro, Wei Guo, Florentina Teofilovici, Kwok-Kin Wong, Suresh Ramalingam, Mark Huberman, Harry Harper, Timothy Webb, Chandra P. Belani, Alan Sandler, Lin-Chi Chen, Julie Brahmer, Philip Bonomi, Lecia V. Sequist, Howard West, Ravi Salgia, Eugene Paschold, Leora Horn, Vojo Vukovic, Marianna Koczywas, Iman El-Hariry, Jonathan Goldman, Mark A. Socinski
Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein critical to tumor growth and proliferation. In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af70f1f0f27b1a60448b6e5137abbd6
https://doi.org/10.1158/1078-0432.c.6522557.v1
https://doi.org/10.1158/1078-0432.c.6522557.v1
Autor:
Niels Reinmuth, Simonetta Mocci, Filippo de Marinis, Roy S. Herbst, David R. Spigel, Kimberly Komatsubara, Hiroshi Kuriki, Jacek Jassem, Alan Sandler, Mustafa Ozguroglu, Wei Zou, Alain Vergnenegre, Mark McCleland, Giuseppe Giaccone, Enriqueta Felip, X. Wen, Masahiro Morise, Carlos H. Barrios, Yu Deng, Z. Andric, Sarayut Lucien Geater, Ida Enquist
Publikováno v:
New England Journal of Medicine. 383:1328-1339
Background The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line trea...
Autor:
Michael McCleod, Alona Zer, Steven L. McCune, Marcin Kowanetz, Henry Jacob Conter, Hans-Georg Kopp, Tarek Mekhail, Niels Reinmuth, W. Lin, Ahad Sadiq, Lijia Wang, Alan Sandler, Maen A. Hussein, Federico Cappuzzo, V. Archer, Achim Rittmeyer, Davey B. Daniel, Howard Jack West, Tania Ochi Lohmann, Alessandro Morabito
Publikováno v:
The Lancet Oncology. 20:924-937
Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with ch
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75